- About ASF
- What is Autism?
- How Common is Autism?
- Signs and Symptoms of Autism
- Autism Diagnosis
- Following a Diagnosis
- Treatment Options
- Beware of Non-Evidence-Based Treatments
- Statement on Use of Medical Marijuana for People with Autism
- Statement on Use of Applied Behavior Analysis (ABA) for Autism
- Autism and Vaccines
- Autism Science
- Autism Research Strategic Plan
- Research by Topic
- Research by Year
- Interviews with Scientists
- Science Journals
- Autism in the News
- Recommended Reading
- Year End Summaries
- Participate in Research
- NIH ACE Grants
- NIMH Resources
- Autism Research Glossary
- Quick Facts About Autism
- What We Fund
- Funding Calendar
- ASF Funded Research
- Where Are They Now?
- ASF Supported Findings
- Autism Sisters Project
- Baby Siblings Research Consortium
- Get Involved
- Resources for Grantees
- Resources for Families
- Sam’s Sibs Stick Together
- COVID-19 Resources
- Day of Learning
- Contact Us
Research by Topic: Shank3
On this week’s podcast, a study led by Elizabeth Berg in the lab of Dr. Jill Silverman at UC Davis published in the journal Autism Research demonstrated SHANK3’s role in core social communication deficits in a rat model of autism. Rats exhibit both receptive and expressive communication. SHANK3 mutations are seen in those with Phelan-McDermid […]
Mice with a duplication of SHANK3, a gene with strong links to autism, are hyperactive and manic, reports a study published in Nature.The mice produce about 50 percent more SHANK3 protein than their genetically typical counterparts, the scientists found, much like people with an extra copy of the gene do. The mice also show signs of hyperactivity. The team observed on further testing that the SHANK3 mice show behaviors typically seen in people going through manic episodes. The mice are easier to startle, eat more, have disrupted sleeping patterns and show heightened sensitivity to amphetamine. The mice also have spontaneous seizures.
ASF Grantee Publishes Paper in Nature that Brings Insight to Study of Phelan-McDermid Syndrome and AutismPublished October 16, 2013 in Nature
A new study brings important insights about the cellular and molecular mechanisms involved in the loss and gain of synaptic function in human neurons from patients with Phelan-McDermid syndrome and autism. It also provides encouragement that neurons derived from induced pluripotent stem cells of patients will be useful in understanding and developing treatments for neurodevelopmental and psychiatric disorders.
Scientists at the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai have received grants from the National Institutes of Health and the Autism Science Foundation to study Insulin-Like Growth Factor-1 (IGF-1), a promising treatment for subtypes of autism. Clinical Director at the Seaver Autism Center, Dr. Alex Kolevzon, says, “IGF-1 has the potential to be effective in treating Phelan-McDermid Syndrome and other types of autism spectrum disorder. We are very pleased that the NIH and the Autism Science Foundation have recognized this by providing us funding to continue our work in bringing this medication to our patients.
Majority of Individuals with SHANK3 Gene Problems Have Both Autism and Severe Intellectual DisabilityPublished June 11, 2013 in Molecular Autism
Prospective study of 22q13 deletion syndrome and SHANK3 deficiency shows that the majority of individuals with a SHANK3 deficiency show both signs of autism and severe intellectual disability.
ASF Scientific Advisory Board Member, Joe Buxbaum, directed the first prospective study on the effects of Shank3 deficiency on a subtype of autism called 22q13 Deletion Syndrome, also known as Phelan-McDermid Syndrome.
SFARI Gene is an integrated resource for the autism research community. It is a publicly available, curated, web-based, searchable database for autism research. This resource is built on information extracted from the studies on molecular genetics and biology of Autism Spectrum Disorders (ASD). The genetic information includes data from linkage and association studies, cytogenetic abnormalities, and specific mutations associated with ASD.
New genetic variants that increase susceptibility to autism are emerging at a rapid pace from scans for copy number variants (CNVs) deletions or duplications of DNA segments and next-generation sequencing. Given the profusion of data, it seems timely to assess the availability and usefulness of mouse models in which to study these genetic risk factors.
Genetic tests are beginning to shed light on the causes of some autism spectrum disorders.
Scientists track adult regression in Phelan-McDermid Syndrome, which is one of the autism-related syndromes with an identified genetic basis.
A recent study sheds light on how a variety of different mutations in genes that seemingly have little in common can each result in the symptoms of autism. To answer this question, researchers developed a molecular map of protein networks or "interactome" to identify how proteins associated with ASD interact with hundreds of other proteins. […]